Phaseline

Targets › AAVR

AAVR (Dyslexia-associated protein KIAA0319-like protein): drug programs, companies and trials

1 program from 1 company in 3 trials: 2 Phase 3, 1 Phase 2; Infectious disease; next expected readout Nov 2026.

Possible role in axon guidance through interaction with RTN4R..; FUNCTION: (Microbial infection) Acts as a receptor for adeno-associated virus and is involved in adeno-associated virus infection through endocytosis system. (UniProt, Q8IZA0)

Open in Phaseline: the race on AAVR, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Vir BiotechnologyTobevibart
AAV receptor antagonist
AAVRPhase 3Viral HepatitisNov 2026

Conditions

Viral Hepatitis (3)

Modalities

mixed (1)

Companies

Vir Biotechnology (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.